BioViva is opening its research facility in the United Kingdom to do the following: 

 

  • Develop vector technology

  • Identify and select novel promoters

  • Test gene therapies in vitro

  • Optimize gene therapy production and costs

 

 

Our Research Pipeline

 

CELL REPROGRAMMING

We are exploring the transient expression of pluripotency factors for age reversal, through targeted mRNA infusion.

 

MYOEditase

We are exploring an intramuscular gene editing strategy to modulate myostatin expression for the treatment of sarcopenia.

 

OPTIMIZED FOLLISTATIN mRNA

In addition to our initial gene therapy approach for sarcopenia, we are developing an optimized follistatin mRNA platform with self replicating technology to maximize treatment duration and efficacy.

 

NEXT GENERATION hTERT mRNA

Our research team is improving on our original telomerase gene therapy by offering a stable mRNA treatment for enhanced expression and rejuvenation.

 

SENESCENT CELL CLEARANCE

We are researching a unique senolytic strategy involving targeting of cellular senescence markers - leading to the specific destruction of these cells without harming healthy tissue.


Bioviva research will also tackle the following diseases: